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Fluorescently labeled dibenzodiazepinone-type muscarinic acetylcholine receptor (MR) 
antagonists, including dimeric ligands, were prepared using red-emitting cyanine dyes. Probes 
containing a fluorophore with negative charge showed high M2R affinities (pKi (radioligand 
competition binding): 9.10-9.59). Binding studies at M1 and M3-M5 receptors indicated a M2R 
preference. Flow cytometric and high-content imaging saturation and competition binding 
(M1R, M2R and M4R) confirmed occupation of the orthosteric site. Confocal microscopy 
revealed that fluorescence was located mainly at the cell membrane (CHO-hM2R cells). Results 
from dissociation and saturation binding experiments (M2R) in the presence of allosteric M2R 
modulators (dissociation: W84, LY2119620 and alcuronium; saturation binding: W84) were 
consistent with a competitive mode of action between the fluorescent probes and the allosteric 
ligands. Taken together, these lines of evidence indicate that these ligands are useful fluorescent 
molecular tools to label the M2R in imaging and binding studies, and suggest that they have a 
dualsteric mode of action.
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Fluorescence-based techniques have been increasingly used for studying ligand-receptor 
interactions, and hence there is a growing demand for suitable fluorescent receptor ligands. 
Compared with radiolabeled probes, fluorescent ligands are advantageous with respect to safety 
precautions and waste disposal. Moreover, they are applicable to fluorescence microscopy and 
flow cytometry, routine techniques in many laboratories, as well as to various homogeneous 
assay systems requiring specialized multimode plate readers,1-3 such as high-content imaging 
based assays, or polarization based fluorescence anisotropy receptor binding studies.4,5 A 
general issue regarding the design of small-molecule fluorescent ligands is the impairment of 
the bioactivity caused by conjugation to bulky fluorophores. For this reason, the pharmacophore 
(ligand) and the fluorophore are often held apart by a linker or spacer moiety.6-8 There are 
numerous reports on fluorescent probes for GPCRs, for instance for neuropeptide Y,9-14 
histamine,15-19 opioid,20-22 dopamine,23,24 neurotensin,25-28 and adenosine29 receptors. 
Concerning muscarinic acetylcholine receptors (MRs), several fluorescently labeled M1R 
ligands, derived from the M1 subtype preferring MR antagonist pirenzepine, were reported (for 
instance, compound 1, Figure 1A).30,31 Likewise, conjugation of the MR ligands tolterodine, 
telenzepine and AC-42 to fluorescent dyes resulted in probes with high to moderate M1R 
affinity (compounds 2-4, Figure 1A).32-35 Compounds 1 and 4 were reported to bind 
bitopically/dualsterically to the hM1R,30,35 i.e. they bind simultaneously to the orthosteric and 
an allosteric site of the receptor. In contrast to the M1R, reports on fluorescent probes for the 
M2-M5 receptor subtypes, characterized at cloned MRs, are rare: the non-selective fluorescent 
M1R ligands 2 and 3 were reported to exhibit also high M2-M5 receptor and high M2R affinity, 
respectively (Figure 1A),33,36 and pyridinium-styryl-type fluorescent dyes were shown to bind 
to all MR subtypes at medium nanomolar concentrations.37
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Figure 1. (A) Structures, M1R affinities (and M2R binding data, if available) of the reported 
fluorescently labeled M1R ligands 1-430,32-36 (in case of 130 and 2,33 reported Ki values were 
converted to pKi values). (B) Structures and M2R affinities of the dibenzodiazepinone-type MR 
ligand DIBA and the DIBA-derived radioligands [3H]UR-MK259 and [3H]UR-SK59 (reported 
Kd values were transformed to pKd values).38,39
Prompted by the recently reported synthesis and characterization of radiolabeled dualsteric M2R 
antagonists derived from the M2R preferring dibenzodiazepinone DIBA (5)40 (for instance, 
[3H]6 and [3H]7, Figure 1B),38,39 exhibiting high M2R affinity, we conjugated two types of red-
emitting fluorophores to previously reported amine-functionalized dibenzodiazepinone 
derivatives.38,39 This approach yielded twelve fluorescent MR ligands, which were studied with 
respect to their M1R-M5R affinities. Selected fluorescent ligands were characterized by flow 
cytometry and high-content imaging based binding studies as well as by confocal microscopy 
to investigate their applicability as molecular tools. 
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Chemistry. The fluorescent monomeric and dimeric dibenzodiazepinone-type MR ligands 
(10,41 12,41 14,41 16-18,41 20,41 22, 23, 27, 28, 30) were prepared from previously reported 
amine-functionalized precursor compounds (8,42 15,39 21,42 26,38 2939) and the pyrylium dye 9 
as well as the indolinium-type cyanine dye succinimidyl esters 11, 13 and 19 (Scheme 1). The 
latter contain the same fluorophore core structure but differ with respect to attached sulfonic 
acid groups leading to different net charges of the dye (cf. Scheme 1 and Figure 2). Pyrylium 
dyes such as 9, originally developed for the staining of proteins,43 react readily with primary 
amines at pH > 8 to give the corresponding pyridinium adducts (pyridinium-type cyanine dyes), 
which exhibit a large Stokes’ shift and can be excited with an argon laser (488 nm) (cf. Figure 
S2, Supporting Information). 
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Scheme 1. Synthesis of the red-emitting dibenzodiazepinone-type MR ligands (structures also 
shown in Figure 2), containing a pyridinium-type (10, 16) or an indolinium-type (12, 14, 17, 
18, 20, 22, 23, 27, 28, 30) cyanine fluorophore, and reference compound 25. Reagents and 
conditions: (a) triethylamine, DMF, rt, 2 h, 21% (10), 34% (16); (b) DIPEA, DMF, rt, 1-2 h, 
40% (12), 37% (14), 31% (17), 30% (18), 30% (20), 34% (22), 41% (23), 36% (27), 26% (28), 
34% (30).
Treatment of the amine precursors 8 and 15 with 9 in the presence of triethylamine yielded the 
pyridinium-type fluorescent ligands 10 and 16, respectively (Scheme 1). The cyanine labeled 
monomeric MR ligands 12, 14, 17, 18, 20, 22 and 23 were prepared by acylation of amines 8, 
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15 and 21 using the succinimidyl esters 11, 13 or 19 (Scheme 1). Reference compound 2527 
was obtained by treatment of propylamine (24) with succinimidyl ester 19. The homodimeric 
fluorescent MR ligands 27 and 28 were synthesized from amine 26 and compounds 13 and 19, 
respectively. Treatment of amine precursor 29, containing the pharmacophore of 5 and 
pharmacophoric groups of TBPB, a compound described as an allosteric and bitopic M1R 

















































































































































































Figure 2. Structures of the synthesized and investigated fluorescent dibenzodiazepinone-type 
MR ligands.
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The fluorescent ligands 20, 23, 28 and 30 were investigated with respect to their stability under 
assay-like conditions, i.e. in PBS pH 7.4. In all cases, no decomposition was observed by HPLC 
analysis within the incubation period of 48 h (Figure S1, Supporting Information). Interestingly, 
the vessel material (siliconized glass tube) strongly adsorbed compound 28, resulting in a 
reduction of the peak area by approx. 90% after 24 h (Figure S1C, Supporting Information). 
Using other materials (polypropylene and “siliconized” polypropylene tubes) did not lower the 
adsorption of 28 (data not shown). Likewise, adsorption of 30 to the vessel material 
(polypropylene) resulted in a reduction of the peak area by approx. 50% (Figure S1D). 
Adsorption of 30 to a siliconized glass tube was comparable (data not shown). Notably, after 
removal of the aqueous solution after 48 h, most of 28 and 30 could be desorbed and recovered 
by rinsing of the tube with acetonitrile/0.1% aq TFA (1:1 v/v) (Figure S1C and S1D, Supporting 
Information).
Radioligand Competition Binding Studies with [3H]NMS. M1R-M5R affinities of the 
fluorescently labeled dibenzodiazepinone derivatives (10, 12, 14, 16-18, 20, 22, 23, 27, 28 and 
30) were determined at intact CHO-hMxR cells (x = 1-5) using the orthosteric antagonist 
[3H]NMS as radioligand (for competition binding curves see Figure S2, Supporting 
Information). The fluorescent ligands with the lowest M2R affinities within this series of 
compounds (pKi 6.85-8.52; Table 1) contained a fluorophore with positive (+1) net charge (10, 
12, 16, 17) or no net charge (14). Fluorescent ligands containing a fluorophore with negative 
(−1) net charge (20, 23, 28, 30) exhibited the highest M2R affinities (pKi 9.10-9.59). These data 
suggest that the net charge of the fluorophore has an impact on the M2R affinity, becoming 
obvious, in particular, in case of compounds 17, 18 and 20, which contain the same 
pharmacophore, linker and fluorophore core structure, but vary with respect to the fluorophore 
net charge (cf. Figure 2, Table 1). The complete MR selectivity profile was determined for 
fluorescent ligands 10, 12, 14, 16-18, 20, 23, 28 and 30 (Table 1). Whereas compounds 23 and 
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30 exhibited a modest preference for the M2R over the M1 and M4 receptor, the other 
compounds proved to be rather non-selective with respect to M1, M2 and M4 receptor binding 
(Table 1). A clear M2R over M3R and M5R selectivity was observed for 16, 18, 20, 23, 28 and 
30 (difference in pKi > 1.5 log units). Some [3H]NMS displacement curves revealed steep curve 
slopes (for instance, in case of compound 17 (M2R): slope = −2.3), indicating a complex 
mechanism, e.g., an involvement of more than one binding site, receptor oligomerization or the 
existence of multiple conformational receptor states.48-51
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Table 1. M2 (and M1, M3-M5) receptor affinities (pKi values) of the fluorescent DIBA 
derivatives 10, 12, 14, 16-18, 20, 22, 23, 27, 28 and 30, as well as of the precursor compounds 
8, 15, 21, 26 and 29 obtained from equilibrium competition binding studies with [3H]NMS at 
live CHO-hMxR cells (x = 1-5).a
M1R M2R M3R M4R M5Rcompd.
pKi slopeb pKi slopeb pKi slopeb pKi slopeb pKi slopeb
8 - 7.97 ± 0.03c
−0.98 ± 
0.07 - - -
























































































































































21 - 9.23 ± 0.10c
−0.82 ± 
0.10 - - -
22 - 9.03 ± 0.08
−1.4 ± 
0.1 - - -



















26 - 9.57 ± 0.07
−1.9 ± 
0.3 - - -
27 - 8.85 ± 0.07
−1.5 ± 
0.2 - - -



















29 8.79e −1.2e 9.71e −1.4e 7.77e −1.2e - -



















aPresented are mean values ± SEM from two (23, M5R) or at least three independent experiments (performed in 
triplicate). Kd values (reported previously42)/applied concentrations of [3H]NMS: M1, 0.12/0.2 nM; M2, 0.090/0.2 
nM; M3, 0.089/ 0.2 nM; M4, 0.035/0.1 nM; M5, 0.24/0.3 nM. bCurve slope of the four-parameter logistic fit. cData 
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were previously reported as pIC50 values by Keller et al. and were reanalyzed to give pKi values.42 dSlope different 
from unity (P < 0.05). eShe et al.39
M2R antagonism. The fluorescently labeled dibenzodiazepinone derivatives 18, 20, 23 and 28 
were investigated in an IP1 accumulation assay at 37 °C using live HEK-293 cells transiently 
transfected with the hM2R and the hybrid G-protein Gαqi5‑HA38,52. Compounds 18, 20, 23 and 
28 did not elicit IP1 accumulation when studied in agonist mode (Figure 3A). In antagonist 
mode, 18, 20, 23 and 28 as well as the reference antagonist atropine (31) fully inhibited IP1 
accumulation elicited by carbachol (CCh) (0.3 μM, ≈ EC80) (Figure 3B), demonstrating that the 
studied fluorescent ligands are M2R antagonists. As previously reported for the 
dibenzodiazepinone-type MR antagonists 6 and 7 (structures cf. Figure 1B), the antagonistic 
potencies of 18, 20, 23 and 28 (Table 2) were considerably lower compared to binding data (pKi 
values) obtained from radioligand competition binding studies (Table 1). Increasing the 
incubation times in the M2R IP1 assay from 30 min to 180 min (preincubation of the cells with 
antagonist) and from 60 min to 90 min (continued incubation after addition of the agonist CCh), 
as well as lowering the temperature from 37 °C to 22 °C during preincubation, did not affect 
(18, 28) or led to a moderate increase (20, 23) in pIC50 values (Table 2). Possibly, the type of 
interaction between 18, 20, 23 or 28 and CCh is different from how the small antagonist 31 
inhibits the CCh induced IP1 accumulation, which is supported by a much better correlation of 
the pIC50 (pKb) and pKi value in case of 31 (pIC50: 8.09 (Table 2), corresponding pKb: 8.66, 
pKi: 9.04 (Table 6)). Therefore, pKb estimates were not calculated for 18, 20, 23 and 28.
The fluorescent ligands 18, 20, 23 and 28 were also investigated in an M4R IP1 accumulation 
assay using intact HEK-293 cells transiently transfected with the hM4R and the hybrid G-
protein Gαqi5 ‑ HA. For these studies, only the aforementioned “long incubation” conditions 
(M2R) were applied.
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Figure 3. Investigation of M2R and M4R agonism and antagonism of compounds 18, 20, 23 
and 28 in IP1 accumulation assays using HEK-hM2-Gαqi5-HA and HEK-hM4-Gαqi5-HA cells, 
respectively. (A) Effect of CCh, 18, 20, 23 and 28 on the M2R mediated accumulation of IP1. 
18, 20, 23 and 28 elicited no response. Data of CCh represent means ± SD from 14 independent 
experiments performed in duplicate. Data of 18, 20, 23 and 28 represent means ± SEM from 
three (20, 23) or four (18, 28) independent experiments performed in duplicate. pEC50 of CCh: 
6.95 ± 0.12 (mean ± SD, n = 14). (B) Inhibition of the CCh (0.3 μM) induced IP1 accumulation 
(M2R) by 18, 20, 23, 28 and atropine (pIC50 values see Table 2). Cells were either preincubated 
with the antagonist at rt for 30 min followed by addition of CCh and continued incubation for 
60 min (short incubation) or were preincubated with the antagonist at 22 °C for 180 min 
followed by addition of CCh and continued incubation at 37 °C for 90 min (long incubation). 
Data represent means ± SEM (number of individual experiments see Table 2). (C) Effect of 
CCh, 18, 20, 23 and 28 on the M4R mediated accumulation of IP1. 18, 20, 23 and 28 elicited 
no response. Data represent means ± SEM from four (18, 20, 23, 28) or six (CCh) independent 
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experiments, each performed in duplicate. pEC50 of CCh: 7.42 ± 0.02 (mean ± SEM, n = 6). 
(D) Inhibition of the CCh (0.1 μM) induced IP1 accumulation (M4R) by 18, 20, 23, 28 (pIC50 
values see Table 2). Cells were preincubated with the antagonist at 22 °C for 180 min followed 
by addition of CCh and continued incubation at 37 °C for 90 min. Data represent means ± SEM 
(number of individual experiments see Table 2).
As in case of the M2R IP1 assay, compounds 18, 20, 23 and 28 did not elicit IP1 accumulation 
when studied in agonist mode (Figure 3C), but completely inhibited IP1 accumulation elicited 
by carbachol (0.1 μM, ≈ EC80) when studied in antagonist mode (Figure 3D). The pIC50 values 
from the M4R IP1 assay were marginally lower than the respective pIC50 values obtained from 
the M2R IP1 assay (Table 2), reflecting lacking M2R selectivity (towards M4R) identified in 
radioligand competition binding studies (Table 1). 
Table 2. Antagonistic activities of 18, 20, 23 and 28 obtained from M2R and M4R IP1 
accumulation assays. 
M2R M4R
short incubation long incubation long incubationcompd.
pIC50a nb pIC50a nb pIC50c nb
18 7.31 ± 0.15 4 7.22 ± 0.12 9 7.04 ± 0.09 8
20 6.65 ± 0.09 6 7.41 ± 0.05 7 6.99 ± 0.07 6
23 6.45 ± 0.14 6 7.24 ± 0.05 7 6.86 ± 0.03 6
28 7.62 ± 0.19 4 7.76 ± 0.12 8 7.43 ± 0.04 10
31 (atropine) 8.09 ± 0.03 5 n.d. - n.d. -
aInhibition of the CCh (0.3 μM, ≈ EC80) induced IP1 accumulation in HEK-hM2-Gαqi5-HA cells. Cells 
were preincubated with the antagonist at rt for 30 min followed by addition of CCh and continued 
incubation for 60 min (short incubation), or were preincubated with the antagonist at 22 °C for 180 
min followed by addition of CCh and continued incubation at 37 °C for 90 min (long incubation). 
Inhibition curves are shown in Figure 3. Data represent mean values ± SEM from n independent 
experiments. bNumber of individual experiments (each performed in duplicate). cInhibition of the CCh 
(0.1 μM, ≈ EC80) induced IP1 accumulation in HEK-hM4-Gαqi5-HA cells. Cells were preincubated with 
the antagonist at 22 °C for 180 min followed by addition of CCh and continued incubation at 37 °C 
for 90 min. Inhibition curves are shown in Figure 3. Data represent mean values ± SEM from n 
independent experiments.
n.d.: not determined
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Fluorescence properties. The fluorescence quantum yields were determined (reference: cresyl 
violet perchlorate) for the fluorescent ligands 16-18, 20, 22, 23 and 28 in PBS (pH 7.4) and in 
PBS supplemented with 1% bovine serum albumin (BSA) to estimate the influence of proteins 
on the quantum yield (Table 3). The selected set of compounds covered all types of fluorophores 
used in this work. All investigated fluorescent ligands showed a higher quantum yield in PBS 
supplemented with 1% BSA compared to PBS alone (Table 3). This phenomenon was 
previously observed for fluorescently labeled NPY Y1 and Y4 receptor ligands, too,12,14 and can 
be explained by interactions (hydrophobic, electrostatic) of the fluorophores with the protein, 
resulting in a changed chemical environment and reduced molecular motion (increased rigidity) 
of the fluorophore.
Table 3. Fluorescence properties of the MR ligands 16-18, 20, 22, 23 and 28 in PBS and PBS 
containing 1% BSA: excitation/emission maxima and fluorescent quantum yields Φ (reference: 
cresyl violet perchlorate).
PBS PBS + 1% BSA
compd. type/net charge of cyanine dye (cf. Figure 2) λex/λem [nm] Φ (%) λex/λem [nm] Φ (%)
16 pyridinium/+1 460/713 8.9 484/643 23.8
17 indolinium/+1 645/663 19.1 655/675 42.1
18 indolinium/0 648/665 20.9 660/678 30.1
20 indolinium/−1 653/669 17.7 656/672 29.0
22 indolinium/0 645/666 24.4 663/676 51.1
23 indolinium/−1 651/669 21.6 658/673 36.8
28 indolinium/−1 650/668 -a 658/673 43.4
aDue to the strong adsorption of 28 to the cuvette when dissolved in PBS without BSA, the determination of Φ failed.
Excitation and corrected emission spectra of 16-18, 20, 22, 23 and 28 in PBS containing 1% 
BSA (Figure S2, Supporting Information) revealed that the pyridinium-type fluorescent ligand 
16 can be excited with an argon laser and the indolinium-type cyanine dye labeled compounds 
(17, 18, 20, 22, 23 and 28) are suited for an excitation with a red diode laser (635 nm).
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Flow cytometric binding studies. The fluorescent ligands 18, 20, 23, 28 and 30 were applied 
in flow cytometric saturation binding studies using intact CHO-hM2R cells. The obtained pKd 
values of 8.59, 9.05, 8.35, 8.51 and 9.19, respectively (Table 4), were in good agreement with 
the binding data from competition binding studies with [3H]NMS (cf. Table 1). At 
concentrations corresponding to the Kd value, unspecific binding was around 10% (18, 20, 23, 
30) or below 5% (28) of totally bound fluorescent ligand (Figure 4). The saturation binding 
experiments revealed that 18, 20, 23, 28 and 30 bind to the orthosteric binding site of the hM2R, 
because the orthosteric antagonist atropine (31) (for structure see Figure S4, Supporting 
Information), used to determine unspecific binding, was capable of completely preventing one-
site (monophasic) specific M2R binding of these fluorescent ligands. Saturation binding 
experiments with 20 were also performed at CHO-hM1R and CHO-hM4R cells, yielding pKd 
values of 8.19 and 8.02, respectively (Table 4; Figure S5, Supporting Information), which were 
again in good accordance with binding data from radioligand competition binding studies (cf. 
Table 1).
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Figure 4. Representative saturation isotherms (specific binding, dashed line) obtained from flow 
cytometric saturation binding experiments performed with 18 (A), 20 (B), 23 (C), 28 (D) and 
30 (E) at intact CHO-hM2R cells. Unspecific binding was determined in the presence of 
atropine (31, for structure see Figure S4, Supporting Information) (500-fold excess to 18, 20, 
23, 28 or 30). Cells were incubated with the fluorescent ligands at 22 °C in the dark for 2 h 
(experiments performed in duplicate). Measurements were performed with a FACSCalibur flow 
cytometer (Becton Dickinson). In the case of total and unspecific binding, data represent mean 
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values ± SEM. In the case of specific binding, data represent calculated values ± propagated 
error.
Table 4. M1R binding data of 20, 23 and 28, M2R binding data of 18, 20, 23, 28 and 30, and M4R binding 
data of 20 determined by saturation binding.
pKda (flow cytometry)fluorescent 
ligand hM1R hM2R hM4R
18 - 8.59 ± 0.09 -
20 8.19 ± 0.02 9.05 ± 0.04 8.02 ± 0.03
23 - 8.35 ± 0.06 -
28 - 8.51 ± 0.08 -
30 - 9.19 ± 0.02 -
pKda (high-content imaging)
hM1R hM2R -
18 - 8.06 ± 0.04
20 - 8.33 ± 0.03
23 7.58 ± 0.04 7.94 ± 0.02
28 8.00 ± 0.05 8.25 ± 0.04
aDetermined by saturation binding at intact CHO-hMxR 
cells (x = 1,2,4) at 22 °C using a FACSCalibur flow 
cytometer or an IX Ultra Confocal Plate Reader (high-
content imaging); mean values ± SEM (pKd) from at least 
two independent experiments performed in duplicate (flow 
cytometry) or triplicate (high-content imaging).
The association and dissociation kinetics of 20, 23 and 28 were determined by flow cytometry 
at intact CHO-hM2R cells at 22 °C using ligand concentrations which corresponded 
approximately to the Kd values of 20, 23 and 28 determined by flow cytometry at CHO-hM2R 
cells (cf. Table 4). The association of 20, 23 and 28 to the M2R appeared to be monophasic 
(Figure 5, kobs and kon values summarized in Table 5). For M2R dissociation studies with 20, 23 
and 28, cells were preincubated with the fluorescent ligand for 180, 120 and 110 min, 
respectively, applying ligand concentrations corresponding approximately to three times the Kd. 
The dissociations of 20, 23 and 28 were followed over 9 h. Data analysis by a three-parameter 
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equation described an incomplete monophasic decline (koff values given in Table 5). The 
dissociation plateaus were different from zero (one-tailed t-test, P < 0.05 (20, 23) or < 0.02 
(28)), indicating a minor component of long lasting M2R binding of the studied fluorescent 
ligands (observed plateau values: 23%, 5% and 22%, respectively; Figure 5). Such a 
phenomenon can be explained by conformational adjustments of the receptor upon ligand 
binding53 or by an enhanced rebinding mediated by a simultaneous interaction with more than 
one binding site.54 The kinetically derived dissociation constants Kd(kin) of 20, 23 and 28 were 
in good agreement with the Kd values obtained from flow cytometric saturation binding studies 
(Table 5). 
Compound 23, showing the fastest dissociation of the studied ligands (20, 23, 28) was chosen 
to perform dissociation experiments in the presence of the allosteric M2R modulators W84 
(32),55-57 LY2119620 (33)58,59 or alcuronium (34)60,61 (Structures see Figure S4, Supporting 
Information). The allosteric ligands, used at a high concentration of 100 µM, did not reduce the 
observed dissociation rate of 23 from the M2R as previously observed for the structurally related 
radioligands [3H]6 and [3H]7.38 These results are consistent with competitive interactions and 
an overlapping binding site between 23 and the allosteric modulators 32-34. They suggest a 
dualsteric binding mode of 23 to the orthosteric and allosteric pocket at the M2R, and by 
implication a similar mode of action for the structurally related fluorescent M2R ligands 10, 12, 
14, 16-18, 20, 22, 27, 28 and 30.  
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Figure 5. Association and dissociation kinetics of 20 (panel A), 23 (panel B) and 28 (panel C) 
determined by flow cytometry at intact CHO-hM2R cells at 22 °C. The dissociation was 
determined in the presence of an excess of atropine (31). (A, left) Association of 20 (1 nM) to 
the M2R; inset: ln[Beq/(Beq−Bt)] versus time. (A, right) Dissociation of 20 (preincubation: 3 nM, 
180 min) from the M2R. (B, left) Association of 23 (5 nM) to the M2R; inset: ln[Beq/(Beq−Bt)] 
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versus time. (B, right) Dissociation of 23 (preincubation: 15 nM, 120 min) from the M2R. 
Addition of the allosteric M2R modulators 32, 33 or 34 at a high concentration (100 µM) did 
not slow down the dissociation of 23 indicating a competitive mechanism between 23 and the 
allosteric M2R ligands. (C, left) Association of 28 (3.5 nM) to the M2R; inset: ln[Beq/(Beq−Bt)] 
versus time. (C, right) Dissociation of 28 (preincubation: 10 nM, 110 min) from the M2R. Data 
in A-C represent the mean ± SEM from three or four independent experiments (performed in 
duplicate). Dissociation data were analyzed by a three-parameter equation describing an 
incomplete monophasic decline because the curve plateau mean values (23%, 5% and 22%, 
respectively) from individual experiments (analyzed by a three-parameter equation) were 
different from zero (P < 0.05, < 0.05 and < 0.02, respectively). The association and dissociation 
rate constants derived from non-linear curve fitting are summarized in Table 5.
Table 5. Parameters characterizing the association of 20, 23 and 28 to, and their dissociation from the 
hM2R, determined at CHO-hM2R cells at 22 ± 1 °C.
compd. Kd(sat) [nM]a Kd(kin) [nM]b kobs [min−1]c kon [min−1 . nM−1]d koff [min−1]e 
20 0.91 0.48 ± 0.22 0.014 ± 0.002 0.0095 ± 0.0028 0.0045 ± 0.0007
23 4.6 1.9 ± 0.6 0.026 ± 0.001 0.0037 ± 0.0005 0.0069 ± 0.0011
28 3.2 1.4 ± 0.5 0.024 ± 0.003 0.0049 ± 0.0011 0.0031 ± 0.0004
aDissociation constant (given for comparison with Kd(kin)) determined by flow cytometric saturation binding at 
CHO-hM2R cells (data taken from Table 4). bKinetically derived dissociation constant (± propagated error) 
calculated from kon and koff. cObserved association rate constant obtained from two-parameter non-linear fits 
(exponential rise to a maximum); mean values ± SEM from three (23, 28) or four (20) independent experiments 
performed in duplicate. dAssociation rate constant ± propagated error, calculated from kobs, koff and the applied 
radioligand concentration (cf. Figure 5 and experimental section). eDissociation rate constant obtained from three-
parameter non-linear fits (incomplete monophasic exponential decline); mean ± SEM from three (20, 28) or four 
(23) independent experiments performed in duplicate.
Confocal microscopy. Binding studies with compounds 20, 23 and 28 at live CHO-hM2R cells, 
using confocal microscopy, revealed a marked difference between total and unspecific binding 
in all cases (Figure 6). Over the whole incubation period (45 min), the major fraction of detected 
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fluorescence appeared to be associated with the plasma membrane, and a substantial increase 
in intracellular fluorescence over time was not observed.
Figure 6. Binding of the fluorescent ligands 20 (A), 23 (B) and 28 (C) (each 30 nM) to live 
CHO-hM2R cells at 30 °C, visualized by confocal microscopy (excitation: 633 nm, emission: 
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638-759 nm) after 5, 25 and 45 min. Unspecific binding was determined in the presence of 
atropine (31, 10 μM). Upper panels show ligand fluorescence alone (greyscale) and overlay 
panels merge ligand fluorescence (green) and nuclei (blue). Images (representative of at least 
three experiments) were acquired with a Zeiss LSM 710 confocal microscope.
High-content imaging. The fluorescent ligands 18, 20, 23 and 28 were also applied in high-
content imaging binding assays, allowing a higher sample throughput compared to flow 
cytometers. In order to reduce background fluorescence, a wash step was performed 
immediately before measurement (exemplified for 23 in Figure S8, Supporting Information) 
Saturation binding experiments with 18, 20, 23 and 28 at live CHO-hM2R cells revealed pKd 
values (8.06, 8.33, 7.94 and 8.25, respectively), which were slightly lower compared to pKd 
values obtained by flow cytometric saturation binding studies (Table 4, Figure 7). These 
deviations might be attributed to the different techniques used, requiring different types of 
fluorescence analysis (flow cytometry: analysis of single, suspended cells passing a laser beam; 
high-content imaging: acquisition of fluorescence images of adherent cells, fluorescence 
quantification by granularity analysis). Moreover, in case of high-content imaging, high 
unspecific binding at higher fluorescent ligand concentrations (cf. Figure S8, Supporting 
Information) might affect the free concentration of fluorescent ligand, resulting in lower 
apparent pKd values.
In addition to M2R binding studies, saturation binding experiments with 23 and 28 were 
performed at CHO-hM1R cells (Figure S6, Supporting Information) yielding pKd values of 7.58 
and 8.00, respectively (Table 4). Binding experiments with reference compound 25 at CHO-
hM2R cells revealed that the fluorescent dye itself was not capable of staining the cells (Figure 
S9, Supporting Information).
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Figure 7. Representative saturation isotherms (specific binding, dashed line) obtained from 
high-content imaging saturation binding experiments performed with 18 (A), 20 (B), 23 (C) 
and 28 (D) at intact CHO-hM2R cells. Unspecific binding was determined in the presence of 
atropine (500-fold excess to 18, 20, 23 or 28). Cells were incubated with the fluorescent ligands 
at 22 oC in the dark for 1 h followed by a wash step and immediate measurement with an IX 
Ultra Confocal Plate Reader (Molecular Devices). Experiments were performed in triplicate. In 
the case of total and unspecific binding, data represent mean values ± SEM. In the case of 
specific binding, data represent calculated values ± propagated error.
In order to further support the hypothesis of dualsteric binding of the fluorescent ligands to the 
M2R (concluded, e.g. from dissociation experiments with 23 in the presence of various allosteric 
M2R modulators; see Figure 5B), saturation binding experiments were performed with 20, 23 
and 28 in the presence of the negative allosteric M2R modulator 32 (structure see Figure S4, 
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Supporting Information),55-57 applied at increasing concentrations (Schild-like analysis, Figure 
8). This kind of experiment is equivalent to the Schild analysis used to investigate the inhibiting 
effect of a receptor antagonist on the response elicited by an agonist,62-64 and was applied, for 
instance, to prove the dualsteric binding mode of [3H]6 and [3H]7 at the hM2R38,39 as well as of 
a fluorescent pirenzepine derivative at the M1R.31 In the presence of 32, the saturation isotherms 
of both monomeric ligands (20, 23) and of the dimeric ligand 28 were rightward shifted 
resulting in linear ‘Schild’ regressions with a slope not different from unity (Figure 8; Table 
S1, Supporting Information). These results were further indication of a competitive mechanism 
between the allosteric M2R ligand 32 and the fluorescent dibenzodiazepinone-type ligands 20, 
23 and 28.
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Figure 8. Saturation binding of 20 (A), 23 (B) and 28 (C) at the hM2R in the presence of the 
allosteric M2R modulator 32 (for structure see Figure S4, Supporting Information) determined 
at intact CHO-hM2R cells using high-content imaging. Presented are saturation isotherms of 
specific fluorescent ligand binding (left, linear scale; middle, semi-logarithmic scale) and 
‘Schild’ regressions (right) resulting from the rightward shifts (ΔpKd) of the saturation 
isotherms (log(r−1) plotted vs. log(concentration allosteric modulator), where r = 10ΔpKd). 
Increasing concentrations of 32 resulted in a rightward shift of the saturation isotherms of the 
fluorescently labeled dibenzodiazepinone derivatives 20, 23 and 28. In all cases, the slope of 
the linear “Schild” regression was close to unity (for statistical evaluation see Table S1, 
Supporting Information), indicating a competitive interaction between the fluorescent ligands 
and the allosteric modulator 32. Data represent mean values ± SEM from three independent 
experiments (performed in triplicate). Note: In case of the logistic (sigmoidal) fits (middle), 
initial four parameter fitting to allow variation in the Hill factor, did not result in slopes 
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significantly different from unity (P > 0.05) except for ‘20 + 2 µM 32’ (slope = 0.94 ± 0.01, P 
< 0.02) and ‘23 + 0.3 µM 32’ (slope = 1.23 ± 0.04, P < 0.05). As these slopes were still close 
to unity, the data were also analyzed using a fixed slope of 1, which did not affect the respective 
pKd values (deviations < 0.2%).  
The ‘pA2’ values of 32 derived from the ‘Schild’ regressions were in good agreement with a 
reported ‘pA2’ of 3238 and with the pKi values of 32 from equilibrium competition binding 
studies with 20, 23 and 28 (described below; Table S1, Supporting Information). With regard 
to the fact that 20, 23 and 28 address the orthosteric binding site of the M2R (concluded from 
experimental data presented in Figures 4 and 7) the results of the Schild-like analyses suggested, 
as already reported, e.g. for the dibenzodiazepinone-type MR ligands 6 and 7,38,39 a dualsteric 
binding mode of 20, 23 and 28 at the hM2R.
Fluorescence-based competition binding studies. The fluorescent probes 18, 20, 23 and 28 
were applied in competition binding studies at CHO-hM2R cells to determine M2R affinities of 
various reported MR ligands, including orthosteric antagonists (NMS, atropine (31)), 
orthosteric agonists (xanomeline (35), oxotremorine (36)), allosteric modulators (W84 (32),55 
LY2119620 (33)58,59), and dualsteric ligands (6, UR-AP060 (37),38 AF-DX 384 (38)65,66) (for 
structures see Figure S4, Supporting Information, and Figure 1B). In high-content imaging 
binding assays, NMS, compounds 6, 31-33 and 35-37 fully competed for specific hM2R binding 
of 20, 23 or 28, indicating a competitive mechanism between the reported MR ligands and 20, 
23 and 28 (cf. Figure S7B-S7D, Supporting Information). As the allosteric M2R ligands 32 and 
33 were capable of complete displacement of 20, 23 and 28 at the hM2R, these results support 
the hypothesis of a dualsteric binding mode of 20, 23 and 28 at the hM2R, and are consistent 
with the results from the Schild analysis (Figure 8). Flow cytometric competition binding 
experiments with 20 and the reported MR ligands 6, 31-33, 35 and 38 also resulted throughout 
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in complete displacement of 20 (Figure S7E and S7F, Supporting Information). The reference 
compound pKi values (NMS, 6, 31-33, 35-38) against different fluorescent tracers (18, 20, 23 
or 28) were also compared with the pKi values obtained from orthosteric radioligand ([3H]NMS) 
competition binding experiments. Here, the closest correlation between fluorescent and 
radioligand data was observed when using fluorescent ligand 23 (Table 6). One explanation 
may be the nearly fully reversible M2R binding of 23, compared to the persistence of a long 
lasting pseudo-irreversible component identified in 20 and 28 dissociation experiments (Figure 
5).
To discriminate between a competitive and an allosteric interaction of the allosteric M2R 
modulator 32 and the dibenzodiazepinone-type fluorescent MR ligands, the effect of 32 on 
hM2R equilibrium binding of 20, applying a high M2R occupancy by 20 (c = 20 nM, Kd = 0.91 
nM, fractional receptor occupancy: 0.96), was determined. In case of a negative allosteric 
mechanism between 32 and 20, this type of experiment would result in an elevation of the lower 
curve plateau (four-parameter logistic fit), and the pIC50 value of 32 would be unaffected 
compared to the experiment using a concentration of 20 close to its Kd value (such a non-
competitive behavior was previously demonstrated, e.g., for [3H]NMS and 3238). However, as 
shown in Figure S7F (Supporting Information), the lower curve plateau did not increase and 
the pIC50 of 32 was rightward shifted by approx. one order of magnitude, being consistent with 
a competitive mechanism between 20 and 32.
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Table 6. M2R binding data (pKi or pIC50) of various orthosteric (NMS, 31, 35, 36), allosteric 
(32, 33) and dualsteric (6, 37, 38) MR ligands determined by the use of the fluorescent ligands 
18, 20, 23 or 28, and with the orthosteric radioligand [3H]NMS.
compd. labeled ligand used for competition binding studies







pKi* or pIC50** 
(radiochemical) 






−0.83 ± 0.01d 10.01 ± 0.08*
e





























































−1.0 ± 0.3 7.04 ± 0.12*
e
37









−0.75 ± 0.12 - - - - 8.71 ± 0.04*
e
aDetermined by flow cytometric competition binding experiments with 20 (1 nM) at live CHO-hM2R cells; mean 
values ± SEM from at least two independent experiments (performed in duplicate). bCurve slope of the four-
parameter logistic fit. cDetermined by high-content imaging competition binding with 18 (10 nM), 20 (10 nM), 23 
(10 nM) or 28 (10 nM) at intact CHO-hM2R cells; mean values ± SEM from at least two independent experiments 
(performed in duplicate). dSlope different from unity (P < 0.05). eDetermined by competition binding studies with 
[3H]NMS (c = 0.2 nM) at live CHO-hM2R cells; mean values ± SEM from at least two independent experiments 
(performed in triplicate). fPegoli et al,38 pIC50 values were not converted to pKi values as 32 and 33 inhibit 
[3H]NMS binding in a non-competitive manner.
Molecular dynamics (MD) simulations. To model the interactions between the fluorescent 
dibenzodiazepinone derivatives and the M2R, MD simulations (5 µs) of the human M2R bound 
to the fluorescent ligands 23 or 28 were performed by analogy with a MD simulation described 
for 6.38 It should be noted that such short scale MD simulations, starting from a docking pose 
and requiring numerous simplifications, can only give a vague idea of the binding mode, but 
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are by far incapable of describing the whole ligand binding process. According to the simulation 
data, both ligands exhibited comparable orthosteric receptor interactions, which were persistent 
over the whole simulation timeframe (Figure 9A and 9B, Figure S10B, Supporting 
Information). The allosteric vestibule (‘common’ allosteric site) of the hM2R was primarily 
occupied by the linker moieties in 23 and 28 (Figure 9A and 9B), but not by the fluorophores. 
This supports the competitive pharmacological interaction between the fluorescent ligands and 
the allosteric modulator 32 at the hM2R (cf. Figures 5B and 8, and Figure S7F, Supporting 
Information). The monomeric ligand 23 showed no persistent hydrogen bonds except for those 
in the orthosteric binding site, but a cation- interaction with W4227.35, a key residue involved 
in binding of allosteric MR modulators,67 was evident as “allosteric contact” (Figure 9A, Figure 
S10B, Supporting Information). In case of the homodimeric fluorescent ligand 28, hydrogen 
bonds to T842.65, D173ECL2 and E175ECL2, located in the allosteric vestibule and in ECL2, 
respectively, were identified as allosteric interactions (Figure 9B, Figure S10B, Supporting 
Information). Whereas the fluorophore and a part of the linker of 23 showed high flexibility 
over the whole time period of the simulation (Figure 9C), the non-orthosterically bound part of 
the dimeric ligand 28 proved to be considerably less flexible (Figure 9D). This was also evident 
from an RMSD analysis of 23 and 28 (Figure S11, Supporting Information), although one has 
to keep in mind that the RMSD analysis considers the entire ligand structure. As reported 
previously for a MD simulation of the hM2R bound to compound 6, the highly conserved 
D1033.32, which typically interacts with MR agonists,68 formed a cluster with S762.57, W993.28, 
Y4267.39 and Y4307.43 (Figure S10A, Supporting Information) instead of interacting with the 
antagonists 23 and 28. This was also reported for crystal structures of the M1R and M4R in 
complex with an antagonist.69 
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Figure 9. Molecular dynamics simulations (5 µs) of the human M2R (inactive state, PDB code 
3UON70) bound to the fluorescent dibenzodiazepinone derivatives 23 (A, C) or 28 (B, D). (A) 
Cluster 0 binding pose of 23 (shown in purple). (B) Cluster 0 binding pose of 28 (shown in 
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green). In A and B, carbon atoms of amino acids constituting the 
D1033.32/S762.57/W993.28/Y4267.39/Y4307.43 cluster are highlighted in cyan. H-bonds between 
ligand and receptor (yellow dashed lines) were identified for Y1043.33 (o.) and N4046.52 (o.) (A), 
as well as for T842.65 (a.), Y1043.33 (o.), D173ECL2 (a.), E175ECL2 (a.) and N4046.25 (o.) (B). In A, 
π−π-stacking (a.) between ligand and receptor is highlighted as green dashed line, and in B, the 
cation−π-interaction (a.) between ligand and receptor is highlighted as pink dashed line. (C, D) 
Time course of the 5 μs MD simulations of the hM2R bound to 23 (C) or 28 (D) showing 
superimposed snap shots collected every 200 ns. o. = orthosteric, a. = allosteric.
Conclusion
The study presents a series of fluorescence-labeled dibenzodiazepinone-type, M2R subtype-
preferring MR antagonists, comprising compounds with high M2R affinity (pKi > 8.5). 
Saturation binding and dissociation experiments at the M2R in the absence and in the presence 
of allosteric M2R ligands suggested a dualsteric binding mode at the M2R. The application of 
the presented type of fluorescent probes in flow cytometric and high-content imaging binding 
assays as well to confocal microscopy, revealed their suitability as molecular tools to study 
M2R expression in cells and to determine M2R binding affinities of (non-labeled) orthosteric 
and allosteric M2R ligands. As the presented fluorescent M2R ligands lack selectivity towards 
the M1 and M4 receptor, this compound class might be useful for the design and preparation of 
fluorescent probes with high M1R, M2R or M4R affinity, using fluorophores with properties 
compatible with fluorescence based techniques such as (time-resolved-)FRET measurements, 
fluorescence correlation spectroscopy and fluorescence anisotropy based methods. On the other 
hand, the combination of fluorescence labeling with a recently reported approach to increase 
M2R selectivity of dibenzodiazepinone-type MR ligands71 might lead to M2R selective 
fluorescent probes.
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General experimental conditions. Standard chemicals and solvents were purchased from 
commercial suppliers and were used without further purification. Acetonitrile for HPLC 
(gradient grade) was obtained from Merck (Darmstadt, Germany) or Sigma-Aldrich 
(Taufkirchen, Germany). CCh, NMS, atropine (31), W84 (32) and Hoechst 33342 (H33342) 
were purchased from Sigma-Aldrich. Oxotremorine sesquifumarate (36) was from MP 
Biomedicals (Eschwege, Germany) and LY2119620 (33) was purchased from Absource 
Diagnostic (Munich, Germany). AF-DX 384 (38) was from Abcam (Cambridge, UK). The 
indolinium-type cyanine dye succinimidyl esters 11, 13 and 19 were obtained from FEW 
Chemicals (Bitterfeld-Wolfen, Germany). [3H]NMS (specific activity = 80 Ci/mmol) was 
purchased from American Radiolabeled Chemicals Inc. (St. Louis, MO) via Hartman Analytics 
(Braunschweig, Germany). The syntheses of 6,38 8,42 15,39 21,42 25,27 26,38 2939 and 3738 were 
described elsewhere. Xanomeline (35)72 and the pyrylium dye 973 were prepared according to 
described procedures. Millipore water was used throughout for the preparation of buffers and 
HPLC eluents. Polypropylene reaction vessels (1.5 or 2 mL) with screw cap (Süd-Laborbedarf, 
Gauting, Germany) were used for the synthesis of the fluorescent ligands (10, 12, 14, 16-18, 
20, 22, 23, 27, 28 and 30) and for the preparation and storage of stock solutions. NMR spectra 
were recorded on a Bruker Avance III HD 600 equipped with a cryogenic probe (14.1 T; 1H, 
600 MHz) (Bruker, Karlsruhe, Germany). Abbreviations for the multiplicities of the signals are 
s (singlet), d (doublet), t (triplet), tt (triplet of triplet), m (multiplet), and brs (broad-singlet). 
High-resolution mass spectrometry (HRMS) analysis was performed with an Agilent 6540 
UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA) using an 
ESI source. Preparative HPLC was performed with a system from Knauer (Berlin, Germany) 
consisting of two K-1800 pumps and a K-2001 detector. A Kinetex-XB C18 (5 μm, 250 × 21 
mm; Phenomenex, Aschaffenburg, Germany) was used as stationary phase at a flow rate of 15, 
18 or 20 mL/min. Mixtures of acetonitrile and 0.1% or 0.2% aq TFA were used as mobile phase. 
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The detection wavelength was set to 220 nm throughout. The solvent of the collected fractions 
was removed by lyophilization using an Alpha 2-4 LD apparatus (Martin Christ, Osterode am 
Harz, Germany) equipped with a RZ 6 rotary vane vacuum pump (Vacuubrand, Wertheim, 
Germany). For compounds 10, 12, 14, 16-18 and 20 analytical HPLC analysis (purity control) 
was performed on a system from Merck-Hitachi (Hitachi, Düsseldorf, Germany) composed of 
a L-6200-A pump, an AS-2000A autosampler, a L-4000A UV detector and a D-6000 interface. 
A Kinetex-XB C18, 5 μm, 250 × 4.6 mm (Phenomenex) was used as stationary phase at a flow 
rate of 0.8 mL/min. Mixtures of 0.1% aq TFA (A) and acetonitrile (B) were used as mobile 
phase (degassed by helium purging). The following linear gradient was applied: 0-30 min: A/B 
95:5-15:85, 30-32 min: 15:85-5:95, 32-40 min: 5:95. The oven temperature was set to 25 °C 
and detection was performed at 220 nm. Analytical HPLC analysis of compounds 20 (chemical 
stability), 22, 23, 27, 28 and 30 was performed with a system from Agilent Technologies 
composed of a 1290 Infinity binary pump equipped with a degasser, a 1290 Infinity 
autosampler, a 1290 Infinity thermostated column compartment, a 1260 Infinity diode array 
detector, and a 1260 Infinity fluorescence detector. A Kinetex-XB C18, 2.6 μm, 100 × 3 mm 
(Phenomenex) served as stationary phase at a flow rate of 0.5 mL/min. Mixtures of 0.04% aq 
TFA (A) and acetonitrile (B) were used as mobile phase. The following linear gradients were 
applied: compounds 22, 23, 27, 28 and 30 (purity): 0-20 min: A/B 85:15-50:50, 20-22 min: 
50:50-5:95, 22-28 min: 5:95; compounds 20 and 30 (chemical stabilities): 0-20 min: A/B 90:10-
68:32, 20-22 min: 68:32-5:95, 22-26 min: 5:95. The oven temperature was set to 25 °C and 
detection was performed at 220 nm. Stock solutions (1, 5 or 10 mM) of fluorescent ligands were 
prepared in DMSO and were stored at −78 °C. Sigmacote (Sigma) was used for “siliconization” 
(coating) of glass and polypropylene reaction vessels used for the investigation of the chemical 
stabilities of 20, 23, 28 and 30.
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Compound Characterization. All target compounds (fluorescent ligands 10, 12, 14, 16-18, 
20, 22, 23, 27, 28 and 30) were characterized by HRMS and RP-HPLC analysis. Additionally, 
compounds 10, 12, 14, 17, 18, 20, 22, 23, 27, 28 and 30 were characterized by 1H-NMR (spectra 
shown in the Supporting Information). The HPLC purity of all fluorescent ligands amounted to 
≥96% (220 nm) (chromatograms shown in the Supporting Information).
Screening for pan-assay interference compounds (PAINS). Screening of all target 
compounds for PAINS via the public tool http://zinc15.docking.org/patterns/home,74 yielded 
no hits except for compounds 10 and 16. In case of 10 and 16, the N,N-dimethylaniline partial 
structure was identified as PAIN. The identities of 10 and 16 were proven by HRMS (in case 
of 10 additionally by 1H-NMR) and both compounds exhibited a purity of 98%. Moreover, 
there are no reports on the N,N-dimethylaniline scaffold to exhibit high MR affinity as 
determined for 10 and 16. Therefore, an interference in the radioligand competition binding 
assays by an impurity containing a N,N-dimethylaniline scaffold can be excluded. 
Chemistry: experimental protocols and analytical data of compounds 10, 12, 14, 16-18, 
20, 22, 23, 27, 28 and 30
4-((1E,3E)-4-(4-(Dimethylamino)phenyl)buta-1,3-dien-1-yl)-2,6-dimethyl-1-(4-(1-(2-oxo-
2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)pyridin-1-ium hydrotrifluoroacetate trifluoroacetate (10). The reaction was 
carried out in a 1.5-mL polypropylene reaction vessel equipped with a micro stir bar. Amine 8 
(2.0 mg, 4.92 μmol) and triethylamine (5.0 mg, 6.8 μL, 49 μmol) were dissolved in anhydrous 
DMF (300 μL) followed by the addition of 9 (5.4 mg, 15 μmol) in anhydrous DMF (120 μL) 
and stirring at rt in the dark for 2 h. 10% aq TFA (corresponding to ca. 50 µmol of TFA) was 
added. Purification of the product by preparative HPLC (flow rate: 15 mL/min; gradient: 0-30 
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min: 0.1% aq TFA/acetonitrile 95:5-38:62, tR = 17 min) afforded 10 as a red solid (0.91 mg, 
21%). RP-HPLC (220 nm): 98% (tR = 19.4 min, k = 5.8). 1H-NMR (600 MHz, MeOH-d4) (ratio 
of observed configurational isomers: ca 1.5:1): δ (ppm) 1.38-1.62 (m, 7H), 1.79-1.86 (m, 2H), 
1.91-2.04 (m, 2H), 2.78 (s, 6H), 2.89-2.98 (m, 1H), 2.99-3.10 (m, 7H), 3.42-3.51 (m, 1H), 3.69-
3.83 (m, 2H), 4.32-4.38 (m, 2H), 4.40 (d, J 17 Hz, 0.6H), 4.43 (d, J 17 Hz, 0.4H), 6.57 (d, J 16 
Hz, 1H), 6.74-6.78 (m, 2H), 6.91-7.02 (m, 2H), 7.24-7.36 (m, 2H), 7.36-7.41 (m, 0.4H), 7.41-
7.46 (m, 2H), 7.46-7.55 (m, 2.2H), 7.59-7.73 (m, 5H), 7.73-7.78 (m, 0.4H), 7.88-7.93 (m, 0.6H), 
7.95-7.99 (m, 0.4H). HRMS (ESI): m/z [M]+ calcd. for [C43H50N5O2]+ 668.3959, found: 




trifluoroacetate (12). Compound 12 was prepared from amine 8 (2.2 mg, 5.4 μmol) and 11 
(2.4 mg, 3.6 μmol) according to the procedure for the synthesis of 10, but DIPEA (4.7 mg, 6.3 
μL, 36 μmol) was used instead of triethylamine. Purification by preparative HPLC (flow rate: 
15 mL/min; gradient: 0-30 min: MeCN/0.1% aq TFA/acetonitrile 95:5-10:90, tR = 14 min) 
afforded compound 12 as a dark blue solid (1.62 mg, 40%). RP-HPLC (220 nm): 97% (tR = 
25.9 min, k = 8.0). 1H-NMR (600 MHz, MeOH-d4) (ratio of observed configurational isomers: 
ca 1.5:1): δ (ppm) 1.27-1.35 (m, 4H), 1.39- 1.53 (m, 7H), 1.64-1.70 (m, 2H), 1.712 (s, 6H), 
1.715 (s, 6H), 1.77-1.85 (m, 2H), 1.85-1.97 (m, 2H), 2.17 (t, J 7.4 Hz, 2H), 2.85-2.94 (m, 1H), 
2.98-3.05 (m, 1H), 3.11 (t, J 7.2 Hz, 2H), 3.39-3.46 (m, 1H (interfering with the 13C satellite of 
the solvent residual signal)), 3.61 (s, 3H), 3.67-3.80 (m, 2H), 4.08 (t, J 7.4 Hz, 2H), 4.37 (d, J 
17 Hz, 0.6H), 4.41 (d, J 17 Hz, 0.4H), 6.26 (d, J 14 Hz, 2H), 6.60 (t, J 12 Hz, 1H), 7.23-7.35 
(m, 6H), 7.36-7.43 (m, 2.4H), 7.45-7.54 (m, 4.2H), 7.59-7.65 (m, 1.4H), 7.66-7.70 (m, 0.6H), 
7.72-7.76 (m, 0.4H), 7.88-7.92 (m, 0.6H), 7.95-7.88 (m, 0.4H), 8.19-8.27 (m, 2H). HRMS 
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hydrotrifluoroacetate (14). Compound 14 was prepared from amine 8 (1.9 mg, 4.7 μmol) and 
13 (2.2 mg, 3.1 μmol) according to the procedure for the synthesis of 10, but DIPEA (4.05 mg, 
5.5 μL, 31 μmol) was used instead of triethylamine. Purification by preparative HPLC 
(conditions as used for 12, tR = 15 min) afforded compound 14 as a dark blue solid (1.43 mg, 
37%). RP-HPLC (220 nm): 96% (tR = 24.2 min, k = 7.4). 1H-NMR (600 MHz, MeOH-d4) (ratio 
of observed configurational isomers: ca 1.5:1): δ (ppm) 1.28-1.36 (m, 4H), 1.41-1.55 (m, 7H), 
1.63-1.76 (m, 14H), 1.77-1.89 (m, 3H), 1.90-2.01 (m, 5H), 2.18 (t, J 7.4 Hz, 2H), 2.85-2.96 (m, 
3H), 3.00-3.08 (m, 1H), 3.10-3.16 (m, 2H), 3.39-3.47 (m, 1H (interfering with the 13C satellite 
of the solvent residual signal)), 3.67-3.79 (m, 2H), 4.03-4.16 (m, 4H), 4.37 (d, J 17 Hz, 0.6H), 
4.43 (d, J 17 Hz, 0.4H), 6.23-6.28 (m, 1H), 6.31-6.37 (m, 1H), 6.59-6.67 (m, 1H), 7.22-7.29 
(m, 3.6H), 7.29-7.43 (m, 4.6H), 7.43-7.55 (m, 4.4H), 7.59-7.68 (m, 2H), 7.71-7.76 (m, 0.4H), 
7.86-7.90 (m, 0.6H), 7.93-7.97 (m, 0.4H), 8.17-8.26 (m, 2H). HRMS (ESI): m/z [M+H]+ calcd. 
for [C59H73N6O6S]+ 993.5307, found: 993.5317. C59H72N6O6S · C2HF3O2 (993.32 + 114.02).
4-((1E,3E)-4-(4-(Dimethylamino)phenyl)buta-1,3-dien-1-yl)-2,6-dimethyl-1-(2-(4-(4-(1-
(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)piperazin-1-yl)ethyl)pyridin-1-ium tris(hydrotrifluoroacetate) trifluoroacetate 
(16). Compound 16 was prepared from amine 15 (3.0 mg, 3.1 μmol) and 9 (3.6 mg, 9.9 μmol) 
according to the procedure for the synthesis of 10. Triethylamine: 5.36 mg, 7.4 μL, 52.9 μmol. 
Purification of the product by preparative HPLC (flow rate: 15 mL/min; gradient: 0-30 min: 
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0.1% aq TFA/acetonitrile 85:15-38:62, tR = 12 min) afforded 16 as a red solid (1.31 mg, 34%). 
RP-HPLC (220 nm): 98% (tR = 16.6 min, k = 4.8); HRMS (ESI): m/z [M]+ calcd. for 




ium tris(hydrotrifluoroacetate) trifluoroacetate (17). Compound 17 was prepared from 
amine 15 (5.8 mg, 5.95 μmol) and 11 (3.0 mg, 4.5 μmol) according to the procedure for the 
synthesis of 10, but DIPEA (5.9 mg, 7.9 μL, 45 μmol) was used instead of triethylamine and 
the reaction time was 1 h instead of 2 h. Purification by preparative HPLC (conditions as used 
for 12, tR = 19 min) afforded the product as a dark blue solid (2.06 mg, 31%). RP-HPLC (220 
nm): 97% (tR = 21.9 min, k = 6.6). 1H-NMR (600 MHz, MeOH-d4) (ratio of observed 
configurational isomers: ca 1.5:1): δ (ppm) 1.31-1.41 (m, 4H), 1.42-1.56 (m, 5H), 1.64-1.75 
(m, 16H), 1.78-1.85 (m, 2H), 1.86-1.99 (m, 2H), 2.21 (t, J 7.5 Hz, 2H), ca. 2.5-3.1 (brs, 4H 
(interfering with the next three listed signals)), 2.61-2.67 (m, 2H), 2.87-2.95 (m, 1H), 3.00-3.07 
(m, 3H), ca. 3.1-3.5 (brs, 4H (interfering with the next two listed signals)), 3.31-3.34 (m, 2H 
(interfering with the solvent residual signal)), 3.41-3.48 (m, 1H (interfering with the 13C satellite 
of the solvent residual signal)), 3.62 (s, 3H), 3.68-3.81 (m, 2H), 4.09 (t, J 7.4 Hz, 2H), 4.39 (d, 
J 17 Hz, 0.6H), 4.42 (d, J 17 Hz, 0.4H), 6.26 (d, J 14 Hz, 2H), 6.57-6.64 (m, 1H), 7.23-7.35 
(m, 6H), 7.36-7.43 (m, 2.4H), 7.45-7.55 (m, 4.2H), 7.59-7.66 (m, 1.4H), 7.66-7.71 (m, 0.6H), 
7.72-7.77 (m, 0.4H), 7.88-7.92 (m, 0.6H), 7.95-7.98 (m, 0.4H), 8.20-8.27 (m, 2H). HRMS 
(ESI): m/z [M]+ calcd. for [C62H79N8O3]+ 983.6270, found: 983.6275. C62H79N8O3+· 
C8H3F12O8− (984.37 + 455.09).
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ium-1-yl)butane-1-sulfonate tris(hydrotrifluoroacetate) (18). Compound 18 was prepared 
from amine 15 (3.7 mg, 3.8 μmol) and 13 (2.4 mg, 3.4 μmol) according to the procedure for the 
synthesis of 10, but DIPEA (4.4 mg, 5.9 μL, 34 μmol) was used instead of triethylamine and 
the reaction time was 1 h instead of 2 h. Purification by preparative HPLC (conditions as used 
for 12, tR = 18 min) afforded the product as a dark blue solid (1.59 mg, 30%). RP-HPLC (220 
nm): 96% (tR = 21.3 min, k = 6.4). 1H-NMR (600 MHz, MeOH-d4) (ratio of observed 
configurational isomers: ca 1.5:1): δ (ppm) 1.31-1.62 (m, 9H), 1.65-1.77 (m, 16H), 1.78-1.85 
(m, 2H), 1.86-2.01 (m, 6H), 2.23 (t, J 7.3 Hz, 2H), ca. 2.4-3.6 (brs, 8H (interfering with the next 
five listed signals)), 2.70 (brs, 2H), 2.86-2.97 (m, 3H), 3.01-3.10 (m, 3H), 3.36 (brs, 2H), 3.40-
3.46 (m, 1H (interfering with the 13C satellite of the solvent residual signal)), 3.67-3.81 (m, 2H), 
4.09 (t, J 7.6 Hz, 2H), 4.13 (brs, 2H), 4.38 (d, J 17 Hz, 0.6H), 4.42 (d, J 17 Hz, 0.4H), 6.27 (d, 
J 14 Hz, 1H), 6.34 (d, J 14 Hz, 1H), 6.61-6.68 (m, 1H), 7.23-7.30 (m, 3.6H), 7.30-7.35 (m, 
2.4H), 7.35-7.42 (m, 2.4H), 7.45-7.55 (m, 4.2H), 7.59-7.70 (m, 2H), 7.72-7.76 (m, 0.4H), 7.88-
7.91 (m, 0.6H), 7.95-7.98 (m, 0.4H), 8.20-8.27 (m, 2H). HRMS (ESI): m/z [M+H]+ calcd. for 




indol-1-ium-1-yl)butane-1-sulfonate bis(hydrotrifluoroacetate) (20). Compound 20 was 
prepared from amine 15 (4.5 mg, 4.6 μmol) and 19 (2.3 mg, 2.9 μmol) according to the 
procedure for the synthesis of 10, but DIPEA (4.2 mg, 5.7 μL, 33 μmol) was used instead of 
triethylamine and the reaction time was 1 h instead of 2 h. Purification by preparative HPLC 
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(conditions as used for 12, tR = 15 min) afforded the product as a dark blue solid (1.45 mg, 
30%). RP-HPLC (220 nm): 96% (tR = 18.2 min, k = 18.8). 1H-NMR (600 MHz, MeOH-d4) 
(ratio of observed configurational isomers: ca 1.5:1): δ (ppm) 1.34-1.56 (m, 8H), 1.59-1.78 (m, 
17H), 1.79-1.86 (m, 2H), 1.90-2.04 (m, 6H), 2.18 (t, J 6.8 Hz, 2H), 2.36 (brs, 2H), ca. 2.4 (brs, 
1H), 2.80-3.14 (m, 9H), ca. 3.14-3.60 (brs, 4H (interfering with the next two listed signals)), 
3.17-3.22 (m, 2H (interfering with 13C satellite of the solvent residual signal)), 3.41-3.48 (m, 
1H (interfering with the 13C satellite of the solvent residual signal)), 3.70-3.83 (m, 2H), 4.07 (t, 
J 6.8 Hz, 2H), 4.22 (t, J 7.5 Hz, 2H), 4.38 (d, J 17 Hz, 0.6H), 4.43 (d, J 17 Hz, 0.4H), 6.21 (d, 
J 13 Hz, 1H), 6.45 (d, J 14 Hz, 1H), 6.64-6.71 (m, 1H), 7.24-7.35 (m, 4H), 7.36-7.40 (m, 0.4H), 
7.40-7.48 (m, 2.6H), 7.48-7.55 (m, 2.6H), 7.59-7.70 (m, 2H), 7.72-7.76 (m, 0.4H), 7.81-7.86 
(m, 2H), 7.88-7.91 (m, 0.6H), 7.95-7.98 (m, 0.4H), 8.21 (t, J 13 Hz, 1H), 8.29 (t, J 13 Hz, 1H). 
HRMS (ESI): m/z [M+H]+ calcd. for [C65H85N8O9S2]+ 1185.5875, found: 1185.5896. 




3H-indol-1-ium-1-yl)butane-1-sulfonate bis(hydrotrifluoroacetate) (22). The reaction was 
carried out in a 1.5-mL polypropylene reaction vessel equipped with a micro stir bar. Amine 21 
(7.0 mg, 7.6 μmol) and DIPEA (6.6 mg, 9.0 μL, 51 μmol) were dissolved in anhydrous DMF 
(50 μL) followed by the addition of 13 (3.6 mg, 5.1 μmol) in anhydrous DMF (50 μL) and 
stirring was continued at rt in the dark for 1 h. 10% aq TFA (100 μL) was added and purification 
by preparative HPLC (flow rate: 18 mL/min; gradient: 0-25 min: 0.1% aq TFA/acetonitrile 
85:15-55:45, tR = 18 min) afforded 22 as a dark blue fluffy solid (2.4 mg, 34%). RP-HPLC (220 
nm): 99% (tR = 14.5, k = 14.8). 1H-NMR (600 MHz, MeOH-d4) (ratio of observed 
configurational isomers: ca 1.5:1): δ (ppm) 1.32 (brs, 4H), 1.41-1.56 (m, 5H), 1.64-1.76 (m, 
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14H), 1.77-1.89 (m, 5H), 1.96 (brs, 5H), 2.20 (t, J 7.4 Hz, 2H), 2.57 (t, J 7.1 Hz, 2H), 2.87-2.98 
(m, 5H), 3.01-3.07 (m, 1H), 3.24 (s, 4H), 3.41-3.47 (m, 1H (interfering with the 13C satellite of 
the solvent residual signal)), 3.67-3.81 (m, 2H), 4.09 (t, J 7.4 Hz, 2H), 4.11-4.19 (m, 4H), 4.38 
(d, J 17 Hz, 0.6H), 4.43 (d, J 17 Hz, 0.4H), 6.23-6.28 (m, 1H), 6.32-6.37 (m, 1H), 6.59-6.67 
(m, 1H), 7.23-7.29 (m, 3.8H), 7.30-7.34 (m, 2.2H), 7.34-7.43 (m, 3.4H), 7.44-7.55 (m, 4.2H), 
7.59-7.68 (m, 2H), 7.71-7.76 (m, 0.4H), 7.87-7.90 (m, 0.6H), 7.94-7.97 (m, 0.4H), 8.19-8.26 
(m, 2H), 8.78 (brs, 1H). HRMS (ESI): m/z [M+2H]2+ calcd. for [C67H85N9O7S]2+ 579.8141, 




dimethyl-3H-indol-1-ium-1-yl)butane-1-sulfonate hydrotrifluoroacetate (23). Compound 
23 was prepared from amine 21 (3.2 mg, 3.5 μmol) and 19 (1.9 mg, 2.3 μmol) according to the 
procedure for the synthesis of 22. DIPEA: 3.0 mg, 4.0 μL, 23 μmol. Purification by preparative 
HPLC (conditions as used for 22, tR = 14 min) afforded 23 as a dark blue fluffy solid (1.4 mg, 
41%). RP-HPLC (220 nm): 98% (tR = 10.0, k = 9.9). 1H-NMR (600 MHz, MeOH-d4) (ratio of 
observed configurational isomers: ca 1.5:1): δ (ppm) 1.31 (brs, 4H), 1.36-1.55 (m, 5H), 1.62-
1.68 (m, 2H), 1.69-1.72 (m, 6H), 1.73 (s, 6H), 1.77-1.86 (m, 5H), 1.88-1.98 (m, 3H), 2.01 (brs, 
2H), 2.16 (t, J 7.1 Hz, 2H), 2.55 (t, J 7.1 Hz, 2H), 2.88-2.97 (m, 5H), 3.01-3.08 (m, 1H), 3.15 
(s, 4H), 3.40-3.46 (m, 1H (interfering with the 13C satellite of the solvent residual signal)), 3.69-
3.81 (m, 2H), 4.06 (t, J 6.7 Hz, 2H), 4.16 (t, J 7.2 Hz, 2H), 4.21 (t, J 7.0 Hz, 2H), 4.39 (d, J 17 
Hz, 0.6H), 4.45 (d, J 17 Hz, 0.4H), 6.18-6.23 (m, 1H), 6.49 (d, J 14 Hz, 1H), 6.63-6.69 (m, 1H), 
7.21-7.28 (m, 1.8H), 7.30-7.34 (m, 2.2H), 7.35-7.38 (m, 0.4H), 7.38-7.48 (m, 3.6H), 7.48-7.55 
(m, 2.6H), 7.59-7.63 (m, 0.4H), 7.63-7.69 (m, 1.6H), 7.72-7.76 (m, 0.4H), 7.80-7.86 (m, 2H), 
7.87-7.91 (m, 0.6H), 7.94-7.97 (m, 0.4H), 8.20 (t, J 13 Hz, 1H), 8.28 (t, J 13 Hz, 1H), 8.77 (brs, 
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1H). HRMS (ESI): m/z [M+2H]2+ calcd. for [C67H85N9O10S2]2+ 619.7925, found: 619.7941. 





tetrakis(hydrotrifluoroacetate) (27). Compound 27 was prepared from amine 26 (6.0 mg, 4.6 
μmol) and 13 (2.2 mg, 3.1 μmol) according to the procedure for the synthesis of 22. DIPEA: 
4.0 mg, 5.4 μL, 31 μmol. Purification by preparative HPLC (flow rate: 18 mL/min; gradient: 0-
25 min: 0.1% aq TFA/acetonitrile 85:15-40:60, tR = 16 min) afforded 27 as a dark blue fluffy 
solid (2.6 mg, 36%). RP-HPLC (220 nm): 99% (tR = 13.3, k = 13.5). 1H-NMR (600 MHz, 
MeOH-d4) (ratio of observed configurational isomers: ca 1.5:1): δ (ppm) 1.30 (brs, 8H), 1.38-
1.56 (m, 8H), 1.69 (s, 6H), 1.71 (s, 6H), 1.72-1.77 (m, 2H), 1.78-1.88 (m, 8H), 1.88-1.97 (brs, 
6H), 2.32 (t, J 7.1 Hz, 2H), 2.58 (t, J 7.1 Hz, 4H), 2.85-2.98 (m, 8H), 3.03 (brs, 2H), 3.37 (t, J 
6.0 Hz, 4H), 3.43 (brs, 1H (interfering with the 13C satellite of the solvent residual signal)), 
3.44-3.49 (m, 5H), 3.66-3.82 (m, 4H), 4.06-4.16 (m, 8H), 4.39 (d, J 17 Hz, 1.2H), 4.43 (d, J 17 
Hz, 0.8H), 4.46 (s, 2H), 6.26 (d, J 14 Hz, 2H), 6.51 (t, J 12 Hz, 1H), 7.23-7.29 (m, 5H), 7.29-
7.34 (m, 3H), 7.35 (brs, 2H), 7.36-7.42 (m, 2.6H), 7.44-7.52 (m, 6.6H), 7.59-7.68 (m, 4H), 
7.71-7.75 (m, 0.8H), 7.87-7.90 (m, 1.2H), 7.91 (brs, 2H), 7.94-7.97 (m, 0.8H), 8.16-8.24 (m, 
3H), 8.75 (brs, 2H). HRMS (ESI): m/z [M+4H]4+ calcd. for [C108H133N17O12S]4+ 473.0005, 
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sulfonate tris(hydrotrifluoroacetate) (28). Compound 28 was prepared from amine 26 (6.0 
mg, 4.6 μmol) and 19 (7.6 mg, 3.1 μmol) according to the procedure for the synthesis of 22. 
DIPEA: 4.0 mg, 5.4 μL, 31 μmol. Purification by preparative HPLC (conditions as used for 22, 
tR = 15 min) afforded 28 as a dark blue fluffy solid (2.9 mg, 26%). RP-HPLC (220 nm): 99% 
(tR = 10.4, k = 10.3). 1H-NMR (600 MHz, MeOH-d4) (ratio of observed configurational isomers: 
ca 1.5:1): δ (ppm) 1.30 (brs, 8H), 1.37-1.55 (m, 8H), 1.65-1.74 (m, 14H), 1.76-1.88 (m, 8H), 
1.88-1.97 (m, 4H), 2.00 (brs, 2H), 2.28 (t, J 6.8 Hz, 2H), 2.58 (t, J 7.1 Hz, 4H), 2.86-2.97 (m, 
8H), 3.04 (brs, 2H), 3.35-3.39 (m, 4H), 3.43 (brs, 1H (interfering with the 13C satellite of the 
solvent residual signal)), 3.44-3.48 (m, 5H), 3.67-3.82 (m, 4H), 4.04 (brs, 2H), 4.11 (t, J 7.2 
Hz, 4H), 4.21 (t, J 7.1 Hz, 2H), 4.32 (s, 2H), 4.39 (d, J 17 Hz, 1.2H), 4.44 (d, J 17 Hz, 0.8H), 
6.17 (d, J 13 Hz, 1H), 6.46 (d, J 14 Hz, 1H), 6.55-6.63 (m, 1H), 7.17 (d, J 8.3 Hz, 1H), 7.23-
7.28 (m, 1.6H), 7.29-7.34 (m, 3.4H), 7.34-7.39 (m, 2.6H), 7.39-7.54 (m, 7.6H), 7.58-7.68 (m, 
4H), 7.71-7.76 (m, 1.8H), 7.84 (brs, 1H), 7.87-7.91 (m, 3.2H), 7.93-7.97 (m, 0.8H), 8.12-8.20 
(m, 2H), 8.26 (t, J 13 Hz, 1H), 8.74 (brs, 2H). HRMS (ESI): m/z [M+3H]3+ calcd. for 







tetrakis(hydrotrifluoroacetate) (30). Compound 30 was prepared from amine 29 (5.0 mg, 4.9 
μmol) and 19 (2.6 mg, 3.3 μmol) according to the procedure used for the synthesis of 22. 
DIPEA: 4.3 mg, 6.0 μL, 33 μmol. Purification by preparative HPLC (conditions as used for 22, 
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tR = 14 min) afforded 30 as a dark blue fluffy solid (2.3 mg, 34%). RP-HPLC (220 nm): 97% 
(tR = 9.4, k = 9.2). 1H-NMR (600 MHz, MeOH-d4) (ratio of observed configurational isomers: 
ca 1.5:1): δ (ppm) 1.30-1.60 (m, 9H), 1.64-1.77 (m, 16H), 1.77-1.84 (m, 2H), 1.86-1.98 (m, 
4H), 1.98-2.05 (m, 2H), ca. 2.0-4.3 (brs, 8H (interfering with the next 16 listed signals)), 2.09-
2.15 (m, 2H), 2.24-2.35 (m, 4H), 2.43-2.51 (m, 2H), 2.67 (t, J 6.2 Hz, 2H), 2.82-2.91 (m, 4H), 
2.91-2.98 (m, 1H), 3.01-3.09 (m, 3H), 3.13-3.23 (brs, 2H (interfering with the 13C satellite of 
the solvent residual signal)), 3.32-3.38 (m, 2H), 3.39-3.47 (m, 3H), 3.50 (t, J 6.6 Hz, 2H), 3.66 
(brs, 1H), 3.69-3.83 (m, 6H), 3.98 (brs, 2H), 4.02 (t, J 7.1 Hz, 2H), 4.22 (t, J 7.3 Hz, 2H), 4.36 
(brs, 2H), 4.39 (d, J 17 Hz, 0.6H), 4.44 (d, J 17 Hz, 0.4H), 4.59 (tt, J 12.3, 4.3 Hz, 1H), 6.19 (d, 
J 13 Hz, 1H), 6.48 (d, J 14 Hz, 1H), 6.63 (t, J 12 Hz, 1H), 7.02-7.09 (m, 3H), 7.14 (d, J 8.3 Hz, 
1H), 7.24-7.35 (m, 4H), 7.35-7.54 (m, 5.6H), 7.59-7.70 (m, 3H), 7.72-7.76 (m, 0.4H), 7.81 (brs, 
1H), 7.88-7.91 (m, 0.6H), 7.93 (brs, 1H), 7.95-7.98 (m, 1.4H), 8.14 (t, J 13 Hz, 1H), 8.21 (brs, 
1H), 8.25 (t, J 13 Hz, 1H). HRMS (ESI): m/z [M+3H]3+ calcd. for [C93H121N14O12S2]3+ 
563.2904, found: 563.2916. C93H118N14O12S2 . C8H4F12O8 (1688.17 + 456.09).
Investigation of the chemical stability. The chemical stabilities of 20, 23, 28 and 30 were 
investigated in PBS pH 7.4 at 22 ± 1 °C using siliconized (Sigmacote, Sigma) flat-bottom glass 
tubes (8.2 × 40 mm; Altmann Analytik, Munich, Germany) in case of 20 and 23, and different 
vessel materials (polypropylene, siliconized glass (the same type as for 20 and 23) or coated 
(“siliconized”) polypropylene) for 28 and 30. The incubation was started by the addition of 10 
μL of 1 mM solution of the fluorescent ligand in DMSO to PBS (90 µL) to yield a final 
concentration of 100 μM. After 0, 24 and 48 h, aliquots (20 μL) were taken and added to 1% 
aq TFA/acetonitrile (8:2 v/v) (20 μL). The resulting solutions were analyzed by RP-HPLC 
(analytical HPLC system and conditions see general experimental conditions; tR: 18.2 min (20), 
10.3 min (23), 10.4 min (28), 18.0 min (30)).
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Determination of Fluorescence Quantum Yields. The determination of the fluorescence 
quantum yields of the fluorescently labeled ligands 16-18, 20, 22, 23 and 28, dissolved in PBS 
or PBS containing 1% BSA, was performed with a Cary Eclipse spectrofluorimeter and a Cary 
100 UV/VIS photometer (Varian Inc., Mulgrave, Victoria, Australia) as described previously 
with minor modifications.12 All spectra were recorded using acryl cuvettes (10 × 10 mm, Ref. 
67.755, Sarstedt, Nümbrecht, Germany). Fluorescence spectra were recorded at the slit 
adjustments (excitation/emission) 10/5 nm and 10/10 nm and resulting quantum yields were 
averaged. Table 7 provides an overview of the used concentrations of the fluorescent ligands 
and the applied excitation wavelengths. The concentration of cresyl violet perchlorate in EtOH 
was 2 µM. Fluorescence spectra of cresyl violet perchlorate were recorded using an excitation 
wavelength of 575 nm.
Table 7. Fluorescent ligand concentrations and excitation wavelengths used for the 
determination of fluorescence quantum yields.
concentration [µM] λex [nm]compd.
PBS PBS + 1% BSA PBS PBS + 1% BSA
16 15 12 445 470
17 5 5 600 610
18 3 2 610 620
20 2 2 610 610
22 2.5 2.5 605 610
23 2.5 2.5 604 609
28 2.5 2.5 617 613
Cell culture. CHO-K9 cells, stably transfected with the DNA of human muscarinic receptors 
M1-M5 (obtained from Missouri S&T cDNA Resource Center; Rolla, MO) were cultured in 
HAM’s F12 medium supplemented with fetal calf serum (Biochrom, Berlin, Germany) (10%) 
and G418 (Biochrom) (750 μg/mL).
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IP1 accumulation assays. The M2R IP1 accumulation assay was performed as described 
elsewhere.38 In addition to the previously described conditions used for the investigation of 
M2R antagonism (preincubation of the cells with antagonist at 37 °C for 30 min followed by 
addition of CCh (0.3 µM) and continuation of the incubation at 37 °C for 60 min), cells were 
preincubated with 20 or 23 at 22 °C for 180 min followed by addition of CCh (final 
concentration: 0.3 µM) and continuation of the incubation at 37 °C for 90 min. 
The M4R IP1 accumulation assay was essentially performed as the previously described M2R 
IP1 accumulation assay38 using the cDNA of the human M4R (Missouri S&T cDNA Resource 
Center) to prepare transiently transfected HEK-hM4-Gαqi5-HA cells. To investigate M2R 
antagonism, cells were preincubated with the antagonist at rt for 180 min followed by addition 
of CCh (final concentration: 0.1 µM) and continuation of the incubation at 37 °C for 90 min.
Radioligand competition binding. Equilibrium competition binding experiments with 
[3H]NMS were performed at intact CHO-hMxR cells (x = 1-5) as described previously,42 but 
the total volume per well was 200 µL, i.e., in case of total binding, wells were filled with 180 
µL of L15 medium followed by the addition of L15 medium (20 µL) containing [3H]NMS (10-
fold concentrated). To determine unspecific binding and the effect of a compound of interest 
on [3H]NMS equilibrium binding, wells were filled with 160 µL of L15 medium followed by 
the addition of L15 medium (20 µL) containing 31 or the compound of interest (10-fold 
concentrated) and L15 medium (20 µL) containing [3H]NMS (10-fold concentrated). Samples 
containing fluorescent ligand were incubated in the dark.
Flow cytometry. All flow cytometric binding studies (fluorescent ligands 18, 20, 23, 28 and 
30) were performed with a FACSCalibur flow cytometer (Becton Dickinson, Heidelberg, 
Germany) (saturation and competition binding) or with a FACSCanto II (Becton Dickinson) 
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(association and dissociation experiments), both equipped with an argon laser (488 nm) and a 
red diode laser (635 and 640 nm, respectively). Settings for forward and sideward scatter were: 
FSC: E-1, SSC: 280 V (FACSCalibur), or FSC: 0 V, SSC: 252 V (FACSCantoII). Fluorescence 
was recorded in channel FL-4 (excitation: 635 nm, emission: 661 ± 9 nm, gain: 700-800 V) and 
in cannel APC-A (excitation: 640 nm, emission: 660 ± 10 nm, gain: 510-540 V), respectively. 
Measurements were stopped after counting of 10,000 (FACSCanto II, flow rate: medium) or 
20,000 (FACSCalibur, flow rate: high) gated events. Samples were prepared and incubated (22 
°C, in the dark) in 1.5 mL polypropylene reaction vessels (Sarstedt, Nümbrecht, Germany) or 
50 mL polypropylene vessels (VWR International, Radnor, PA). All experiments were 
performed in duplicate. Cells were seeded in 175-cm2 culture flasks 5-6 days prior to the 
experiment. On the day of the experiment, cells were treated with trypsin, suspended in culture 
medium and centrifuged. The cell pellet was re-suspended in Leibovitz’s L15 culture medium 
(Gibco, Life Technologies, Darmstadt, Germany) supplemented with 1% BSA (in the following 
referred to as L15 medium). The cell density was adjusted to 0.9-1.1 × 106 cells/mL. For 
saturation (18, 20, 23, 28, 30) and competition (20) binding experiments, 1.5 mL reaction 
vessels were prefilled with 490 μL of the cell suspension. For total binding, DMSO/H2O (1:1 
v/v) (5 μL) and DMSO/H2O (1:1 v/v) (5 μL), containing the fluorescent ligand (100-fold 
concentrated), were added. To determine unspecific binding and in case of competition binding, 
DMSO/H2O (1:1 v/v) (5 μL), containing atropine (31) (100-fold concentrated) and the 
compound of interest (100-fold concentrated), respectively, and DMSO/H2O (1:1 v/v) (5 μL), 
containing the fluorescent ligand (100-fold concentrated), were added. For saturation binding 
experiments at the M2R the following final concentrations of fluorescent ligands were applied: 
0.1-15 nM (18), 0.1-10 nM (20), 0.005-50 nM (23), 0.15-80 nM (28) and 0.04-20 nM (30). For 
saturation binding studies at the M1R and M4R, compound 20 was applied at final 
concentrations of 0.15-80 nM. For competition binding experiments with 20, the final 
concentration of 20 was 1 or 20 nM. Unspecific binding was determined in the presence of 31 
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at 500-fold access to the fluorescent ligands. Samples were incubated at 22 °C in the dark under 
gentle shaking for 2 h.
For association experiments with 20 (1 nM), 23 (5 nM) and 28 (3.5 nM) at CHO-hM2R cells, 
50 mL reaction vessels were prefilled with 5 mL (total binding) or 2.5 mL (unspecific binding) 
of the cell suspension. For total binding, DMSO/H2O (2:8 v/v) (50 μL) and DMSO/H2O (1:1 
v/v) (50 μL), containing 20 (100 nM), 23 (500 nM) or 28 (350 nM), were added. To determine 
unspecific binding, DMSO/H2O (2:8 v/v) (25 μL), containing 31 (50, 250 and 175 μM, 
respectively), and DMSO/H2O (1:1 v/v) (25 μL), containing 20 (100 nM), 23 (500 nM) or 28 
(350 nM), were added to the cell suspension followed by incubation under gentle shaking in 
the dark. After different periods of time (1-300 min), aliquots (200 µL) were taken and 
subjected to measurement. In the case of dissociation experiments, cells were preincubated with 
20 (3 nM), 23 (15 nM) or 28 (10 nM) for 180 min (20), 120 min (23) or 110 min (28). Vessels 
and sample volumes were the same as for association experiments. Unspecific binding was 
determined in the presence of 31 at final concentrations of 1.5, 7.5 and 5 μM, respectively. After 
preincubation with the fluorescent ligand under gentle shaking in the dark, the dissociation was 
started by the addition of 31 (100-fold concentrated in DMSO/water (2:8 v/v)) to reach final 
concentrations of 31 of 3, 15 and 10 µM, respectively. After different periods of time (2-540 
min), aliquots (200 µL) were taken and subjected to measurement. Dissociation experiments 
with 23 in the presence of the allosteric M2R ligands 32, 33 or 34, were performed as 
dissociation experiments in the absence of 32-34, but 1 min before the start of the dissociation 
by the addition of 31, compound 32, 33 or 34 (10 µM in DMSO) was added to reach a final 
concentration of 100 µM.
High-content imaging binding experiments. One day prior to the experiment, CHO-hM2R or 
CHO-hM1R cells were seeded at 35,000-40,000 cells per well into the central 60 wells of a 
black clear bottomed 96-well plate (Greiner 655090). On the day of the experiment the medium 
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was removed by suction, the cells were washed with HBSS75 containing 0.1 % BSA (in the 
following referred to as HBSS-BSA) (50 μL), and covered with HBSS-BSA (80 µL) containing 
the permeable nuclear Hoechst dye H33342 (2 μg/mL). To determine total binding (saturation 
and competition binding experiments), HBSS-BSA (10 μL) and HBSS-BSA (10 μL) containing 
the fluorescent ligand (10-fold concentrated) were added. For the determination of unspecific 
binding and to study the effect of a compound of interest on M2R binding of the fluorescent 
ligand (competition binding assay), HBSS-BSA (10 μL) containing 31 or the ‘competitor’ (10-
fold concentrated) and HBSS-BSA (10 μL) containing the fluorescent ligand (10-fold 
concentrated) were added. Samples were incubated at rt in the dark for 60 min. After incubation, 
images were directly acquired with the IX Ultra confocal plate reader (Molecular Devices, 
Sunnyvale CA) (to obtain “non-washing” saturation binding curves) or the cells were washed 
with HBSS-BSA (50 μL) and covered with HBSS-BSA (50 μL) followed by immediate 
acquisition of the images using the IX Ultra confocal plate reader. The washing procedure was 
performed within < 3 min. The excitation laser lines of the Ultra plate reader were 405 nm 
(H33342) and 635 nm (Cy5). Two sites/well were measured throughout. The following final 
concentrations of 18, 20, 23 and 28 were applied for saturation binding studies: 0.1-70 nM (18 
and 20, M2R), 0.4-400 nM (23, M1R), 0.4-200 nM (23, M2R), and 0.2-100 nM (28, M1R and 
M2R). For competition binding experiments at CHO-hM2R cells, 18, 20, 23 and 28 were applied 
at final concentrations of 10 nM. For the determination of unspecific binding, 31 was used at 
500-fold (saturation binding) or 100-fold (competition binding) excess to the fluorescent ligand. 
Saturation binding experiments were performed in triplicate and competition binding assays 
were performed in duplicate. M2R saturation binding experiments with 20, 23 and 28 in the 
presence of 32 (Schild analysis) were performed as described above with the following 
modification: the cells were covered with 70 µL of HBSS-BSA instead of 80 µL to compensate 
the extra addition of HBSS-BSA (10 µL) containing 32 (10-fold concentrated). The washing 
step prior to the measurement was performed.
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Confocal Microscopy. For the investigation of binding of 20, 23 and 28 to CHO-hM2R cells 
by confocal microscopy, a previously described protocol for studying binding of fluorescently 
labeled neurotensin receptor ligands to CHO-hNTS1R cells, was used.27 The final fluorescent 
ligand concentration was 30 nM. Unspecific binding was determined in the presence of 31 (10 
µM). Images were acquired after an incubation period of 5-45 min with a Zeiss LSM 710 
confocal laser scanning microscope (Zeiss, Jena, Germany). The objective was 63× 
magnification with oil (1.4 NA). The excitation laser lines were 405 nm and 633 nm, filter 
settings were 410-514 nm (H33342 channel) and 638-759 nm (Cy5 channel), and the pinhole 
setting was 1.0 airy unit for the Cy5 channel.
Molecular dynamics simulation. For induced-fit docking, ligand (23, 28) geometries were 
energetically optimized using the LigPrep module (Schrödinger LLC). Tertiary amine groups 
and imidazole moieties in 23 and 28 were protonated, and sulfonic acid groups were 
deprotonated resulting in net charges of +1 and +3, respectively. Induced-fit docking 
(Schrödinger LLC) of 23 was performed using the output coordinates of the previously 
described docking of 6 at the hM2R.38 For initial docking, Y1043.33, Y4036.51, and Y4267.39 were 
mutated to alanine, and 23 was docked within a box of 46 × 46 × 46 Å3 around the binding pose 
of 6. For redocking, the extended precision protocol was used. Induced-fit docking of 28 was 
performed using the output coordinates of the docking of 23. Initial docking was performed by 
analogy to that of 23, but core restraints were applied to the N5-((piperidin-1-
yl)ethanoyl)dibenzodiazepinone partial structure with a maximum RMSD of 5 Å based on the 
identical partial structure of 23. For redocking, the mutations of Y1043.33, Y4036.51, and Y4267.39 
to alanine as well as the core restraints were maintained, and, after redocking, a second prime 
refinement stage was applied (including a reversion of the alanine mutations). The binding 
poses, corresponding to the lowest XP GScore, were selected as initial coordinates for MD 
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simulations. The respective ligand-receptor complexes were aligned to the hM2R entry (PDB 
ID: 3UON) in the orientations of proteins in membranes (OPM) database76 using the protein 
structure alignment tool (Schrödinger LLC). The ligand-receptor complexes were inserted into 
a hydrated palmitoyloleoylphosphatidylcholine (POPC) bilayer (comprising 160 POPC 
molecules) as described for 6.38 The systems contained about 62,000 (23) and 65,000 (28) atoms 
and the initial box size was approximately 81 × 81 × 102 Å3 and 81 × 81 × 106 Å3, respectively. 
The parameters (geometry, partial charges) of the protein structure, compounds 23 and 28, 
lipids, inorganic ions, and water were assigned as reported.38 MD simulations were executed 
on Nvidia GTX 1080Ti GPUs (approximately 11.5 TFlops) using the CUDA version of 
PMEMD,77,78 implemented in AMBER18 (AMBER 2018, University of California, San 
Francisco, CA). After minimization, the systems were heated from 0 to 100 °K in the NVT 
ensemble during 20 ps and from 100 to 310 °K in the NPT ensemble during 100 ps, applying 
harmonic restraints of 5 kcal mol−1 Å−1 to non-hydrogen atoms of protein, lipids and ligand. 
The temperature and pressure coupling parameters used for the equilibration at 310 °K (NPT 
ensemble) were the same as described for MD simulations of the hM2R bound to 6.38 During 
the 10 ns equilibration period, harmonic restraints on receptor non-hydrogen atoms were 
reduced stepwise (0.5 kcal mol−1 Å−1 every 0.5 ns) to 0.5 kcal mol−1 Å−1 within 5 ns. Harmonic 
restraints on ligand non-hydrogen atoms were reduced stepwise (0.5 kcal mol−1 Å−1 every 0.5 
ns) to 2.5 kcal mol−1 Å−1 within 3 ns. After 5 and 3 ns, respectively, harmonic restraints on 
receptor and ligand non-hydrogen atoms were removed, i.e. the residual equilibration period (5 
ns) was run without restraints. The interaction cutoff was set to 9.0 Å. Long-range electrostatics 
were computed using the particle mesh Ewald (PME) method.79 To enable a frame step size of 
4 fs, bonds involving hydrogen atoms were constrained using SHAKE80 and hydrogen mass 
repartitioning (HMR)81 was applied. The final frame of the equilibration period was used as 
input for the simulations over 5.25 μs. After the equilibration period of 10 ns, the Berendsen 
Barostat was replaced by the Monte Carlo Barostat algorithm.82 Cluster and H-bond analyses 
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were performed as described,38 but data were collected every 500 ps using every tenth frame (5 
ns step size). The first 250 ns of the simulations were omitted. Figures showing molecular 
structures (Figure 9A-D) were generated with PyMOL Molecular Graphics system, version 
1.8.2.1 (Schrödinger LLC).
Data processing. Retention (capacity) factors were calculated from retention times (tR) 
according to k = (tR−t0)/t0 (t0 = dead time). Data from the IP1 accumulation assay were 
processed as described previously, but pIC50 values were not converted to pKb values.38 Raw 
data from flow cytometric experiments were processed with the aid of the FlowJo software 
(FlowJo LLC, Ashland, OR) to obtain geometrical mean values of FL-4 (FACSCalibur), or 
using the FACSDiva Software (Becton Dickinson) to obtain arithmetic mean values of the 
APC-A channel (FACSCanto II). Fluorescence arbitrary values from high-content imaging 
fluorescence images were obtained using a previously described procedure.13,27 Specific 
binding data from saturation binding experiments (flow cytometry, high-content imaging), 
obtained by subtracting unspecific binding data from total binding data, were plotted against 
the fluorescent ligand concentration and analyzed by a two-parameter equation describing 
hyperbolic binding (one site-specific binding, GraphPad Prism 5, GraphPad Software, San 
Diego, CA) to obtain Kd and Bmax values. Unspecific binding data were fitted by linear 
regression. Additionally, specific binding data were plotted against log(fluorescent ligand 
concentration) and analyzed by a four-parameter logistic fit (log(agonist) vs. response, applied 
constraints: bottom = 0%, top = Bmax of the aforementioned two-parameter hyperbolic fit; 
GraphPad Prism) to obtain pKd values. In case of saturation binding experiments in the presence 
of compound 32, specific binding data were analyzed by a two-parameter equation describing 
hyperbolic binding (one site-specific binding, GraphPad Prism) to obtain Kd and Bmax values. 
Additionally, specific binding data were normalized to the Bmax value, specific binding (%) was 
plotted against log(concentration 20, 23 or 28) followed by analysis using a four-parameter 
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logistic fit (log(agonist) vs. response, applied constraints: bottom = 0%, top = 100%, slope = 1; 
GraphPad Prism). Data for the ‘Schild’ plot were obtained from the rightward shift (ΔpKd) of 
the saturation isotherm and transformation into log(r−1) (where r = 10ΔpKd). Log(r−1) was 
plotted against log(concentration of 32) and the data were analyzed by linear regression to 
obtain the slope and the ‘pA2’ value (intercept with the X axis). Specific binding data from 
association experiments with 20, 23 and 28 (flow cytometry) were analyzed by a two-parameter 
equation describing an exponential rise to a maximum (one-phase association) (SigmaPlot 11.0, 
Systat Software, Chicago, IL) to obtain the observed association rate constant kobs and the 
maximum of specifically bound fluorescent ligand (Beq), which was used to calculate 
specifically bound fluorescent ligand (Bt) in %. Data from dissociation experiments (flow 
cytometry) (% specifically bound fluorescent ligand (Bt) plotted over time) were analyzed by a 
three-parameter equation (incomplete one phase decay, SigmaPlot 11.0). The association rate 
constants (kon) of 20, 23 and 28 were calculated from kobs, koff and the concentration of the 
fluorescent ligand used for the determination of kobs ([fluorescent ligand]) according to the 
equation: kon = (kobs − koff)/[fluorescent ligand]. The kinetically derived dissociation constants 
Kd(kin) of 20, 23 and 28 were calculated according to: Kd(kin) = koff/kon. Total binding data 
from competition binding experiments (radiochemical assays, flow cytometry, high-content 
imaging) were plotted against log(concentration competitor) and analyzed by a four-parameter 
logistic equation (log(inhibitor) vs response - variable slope, GraphPad Prism) followed by 
normalization (100% = “top” of the four-parameter logistic fit, 0% = unspecifically bound 
radioligand or fluorescent ligand) and analysis of the normalized data by a four-parameter 
logistic equation to obtain pIC50 values. The latter were converted to pKi values according to 
the Cheng-Prusoff equation83 (logarithmic form). Statistical significance (curve slopes) was 
assessed by a one-sample, two-tailed t-test. Propagated errors were calculated according to the 
general equation (1) (maximum error propagation).
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(1)∆z =  | ∂f∂x1|∆x1 +  | ∂f∂x2|∆x2 +  …
f: function of x1, x2, etc. (f(x1, x2, …) = z); x1, x2: error (in this work represented by the SEM) 
of x1 and x2; z: (propagated) error of z
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B0, specifically bound (fluorescent) ligand after the pre-incubation (before the start of the 
dissociation) of a dissociation experiment; Beq, estimated maximum of specifically bound 
(fluorescent) ligand of an association experiment; Bt, specifically bound (fluorescent) ligand at 
time “t” of an association or a dissociation experiment; CCh, carbachol; MeCN, acetonitrile; 
CHO-cells, Chinese hamster ovary cells; DIPEA, diisopropylethylamine; GPCR, G-protein 
coupled receptor; HBSS, Hank's balanced salt solution; IP1, inositol monophosphate; k, 
retention (or capacity) factor (HPLC); Kd, dissociation constant obtained from a saturation 
binding experiment; kobs, observed association rate constant; koff, dissociation rate constant; kon, 
association rate constant; MR, muscarinic receptor; NMS, N-methylscopolamine; PBS, 
phosphate buffered saline; pKb, negative logarithm of the dissociation constant Kb (in M) of an 
antagonist determined by inhibition of the response elicited by an agonist (functional assay); 
pKd, negative logarithm of the Kd in M; pKi, negative logarithm of the dissociation constant Ki 
(in M) obtained from a competition binding experiment; RMSD, root mean square deviation; 
TFA, trifluoroacetic acid; tR, retention time.
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